On May 14, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, held its Annual Meeting of Stockholders. During the meeting, a quorum was achieved with 4,947,264 shares represented. The stockholders elected all five nominees for director to serve until the 2025 Annual Meeting or until their successors are elected. The directors elected include Randy Milby, Leonard Mazur, Lynne A. Bui, Sireesh Appajosyula, and Kelly Anderson. Additionally, the appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Stockholders also approved the discretionary authority for the Board of Directors to effect a Reverse Stock Split at a ratio from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. Furthermore, the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan was approved. The meeting concluded with all proposals addressed and the company's report signed by Randy Milby.

On May 14, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, held its Annual Meeting of Stockholders. During the meeting, a quorum was achieved with 4,947,264 shares represented. The stockholders elected all five nominees for director to serve until the 2025 Annual Meeting or until their successors are elected. The directors elected include Randy Milby, Leonard Mazur, Lynne A. Bui, Sireesh Appajosyula, and Kelly Anderson. Additionally, the appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Stockholders also approved the discretionary authority for the Board of Directors to effect a Reverse Stock Split at a ratio from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. Furthermore, the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan was approved. The meeting concluded with all proposals addressed and the company's report signed by Randy Milby.